Abstract
Background Over one quarter of individuals in Sweden report suffering from allergic rhinitis (AR), placing a considerable burden on both sufferers and society [1]. In clinical trials MP2902* (a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in an advanced delivery system) provided complete/near complete symptom control in 1 of 6 moderate/severe seasonal AR (SAR) patients [2] and complete relief in 7 of 10 mild/ moderate perennial AR (PAR) patients [3]. This study aimed to assess the effectiveness of MP29-02* in routine clinical practice.
Highlights
Over one quarter of individuals in Sweden report suffering from allergic rhinitis (AR), placing a considerable burden on both sufferers and society [1]
Patients assessed symptom severity using a visual analog score (VAS) from 0mm to 100mm, in the AM prior to MP29-02* use, on Days 0, 1, 3, 7 and last day. This was described for the whole population and according to phenotype (i.e. seasonal AR (SAR), perennial AR (PAR) or SAR + PAR) and severity
MP29-02* provides effective and rapid symptom control in Swedish AR patients in a real-world setting irrespective of disease phenotype or severity, with responder rates higher than those observed in a clinical trial with moderate/severe AR patients, supporting MP29-02*’s position as the drug of choice for the treatment of AR
Summary
Over one quarter of individuals in Sweden report suffering from allergic rhinitis (AR), placing a considerable burden on both sufferers and society [1]. This study aimed to assess the effectiveness of MP29-02* in routine clinical practice
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
